格隆汇8月19日丨麦迪科技(603990.SH)公布2025年半年度报告，报告期实现营业收入1.35亿元，同比下 降47.24%；归属于上市公司股东的净利润2832.75万元，同比扭亏为盈；基本每股收益0.09元。 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-052 苏州麦迪斯顿医疗科技股份有限公司 第四届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"、"麦迪科技"）第 四届监事会第十七次会议于 2025 年 8 月 18 日以通讯表决的方式召开。本次监事 会会议通知于 2025 年 8 月 8 日以邮件形式发出。会议由监事会主席姜军先生召 集，会议应出席监事 3 名，实际出席监事 3 名，董事会秘书列席了本次会议。会 议召集及召开方式符合《中华人民共和国公司法》和《苏州麦迪斯顿医疗科技股 份有限公司章程》等有关规定，所形成的决议合法有效。 二、监事会会议审议情况 （一）审议并通过了《关于公司 2025 年半年度报告及摘要的议案》； 监事会认为：《麦迪科技 2025 年半年度报告》及其摘要的相关内容编制程序 符合法律法规、规范性文件和《公司章程》的要求，格式和内容符合中国证券监 督管理委员会和上海证券交易所的有 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-051 公司审计委员会审议并通过了本议案。 苏州麦迪斯顿医疗科技股份有限公司 第四届董事会第三十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"、"麦迪科技"）第 四届董事会第三十四次会议于 2025 年 8 月 18 日以通讯表决的方式召开。本次董 事会会议通知于 2025 年 8 月 8 日以邮件形式发出。会议由董事长陈宁先生召集 并主持，会议应出席董事 5 名，实际出席董事 5 名，公司监事会成员及高级管理 人员列席了本次会议。会议召集及召开方式符合《中华人民共和国公司法》和《苏 州麦迪斯顿医疗科技股份有限公司章程》等有关规定，所形成的决议合法有效。 二、董事会会议审议情况 （一）审议并通过了《关于公司 2025 年半年度报告及摘要的议案》； 具体内容详见公司同日披露的《麦迪科技 2025 年半年度报告》及其摘要。 表决结果：同意 5 票；反对 0 票；弃权 0 票。 ...

Financial Performance - The company reported no profit distribution or capital reserve transfer to increase share capital during the reporting period[6]. - The reporting period covers from January 1, 2025, to June 30, 2025[14]. - The company's operating revenue for the first half of 2025 was CNY 135,203,774.76, a decrease of 47.24% compared to the same period last year, primarily due to the completion of the disposal of its photovoltaic business in January 2025[24]. - The total profit for the first half of 2025 increased by CNY 102,424,500, while the net profit attributable to shareholders rose by CNY 104,662,500, indicating a significant recovery in profitability[25]. - The basic earnings per share for the first half of 2025 was CNY 0.09, an increase of CNY 0.34 compared to the same period last year, reflecting improved financial performance[23]. - The weighted average return on net assets increased by 10.74 percentage points to 3.48% compared to the previous year, demonstrating enhanced efficiency in asset utilization[24]. - The net cash flow from operating activities improved by CNY 116,382,400, indicating a positive trend in cash management following the disposal of the photovoltaic business[25]. - The company achieved a revenue of 135.20 million yuan in the first half of 2025, a decrease of 47.24% compared to the same period last year[39]. - The net profit attributable to shareholders was 28.33 million yuan, marking a significant turnaround from a loss in the previous year[39]. - The company reported a significant increase in other receivables, rising to RMB 274,013,461.07 from RMB 5,324,945.58, a growth of approximately 5,144.5%[136]. - The company reported a comprehensive income loss of CNY -76,335,164.46 for the current period, compared to a loss of CNY -75,395,527.06 in the previous period[160]. Corporate Governance - The board of directors and management confirmed the accuracy and completeness of the financial report[5]. - The report is unaudited, and the management has stated the financial report's authenticity[5]. - The company is committed to ensuring the report's authenticity, accuracy, and completeness by all directors[8]. - The company has not faced any violations in decision-making procedures regarding external guarantees[8]. - The company confirmed that the actual controller and shareholders will not seek control of the listed company through any means, with a commitment effective from May 2022[86]. - The company has a long-term commitment to avoid any business competition with its subsidiaries, ensuring compliance with this commitment during the period when the actual controller holds at least 5% of the company's shares[86]. - The company will strictly adhere to market principles for any unavoidable related transactions, ensuring fairness and legality in accordance with regulations[87]. - The company committed to maintaining independent operational assets and financial independence, ensuring no misuse of funds or resources[88]. - The company will establish an independent financial department and accounting system, ensuring no shared bank accounts with related entities[88]. - The company will ensure compliance with legal responsibilities regarding any violations of commitments made during the restructuring process[89]. Market Position and Strategy - The company is focusing on the medical informationization industry, which is projected to reach CNY 84.57 billion in IT spending by 2025, indicating significant market potential[30]. - The reproductive medicine service industry is expected to grow significantly, driven by increasing infertility rates and supportive government policies, with a long-term market potential exceeding CNY 1 trillion[32]. - The company is committed to enhancing its core medical services and leveraging technological advancements to improve operational efficiency and service quality[31]. - The company has established a leading market position in the clinical informationization sector, with its DoCare series and Dorico solutions applied in over 2,400 medical institutions across 32 provinces[45]. - The company is actively collaborating with research institutions and industry partners to strengthen its capabilities in AI and other advanced technologies, aiming to explore new business growth points[49]. Research and Development - The company completed the domestic adaptation and innovation transformation of its critical care software, ensuring compatibility with major domestic hardware and software platforms[40]. - The company integrated AI upgrades into its anesthesia, critical care, and emergency systems, enhancing automated assessment and risk warning capabilities[41]. - The company developed the Youmai AI voice assistant system, which supports multimodal interaction and various AI model integrations[43]. - The company emphasizes the importance of continuous R&D for new products to maintain market competitiveness and avoid technological obsolescence[71]. - The company has not reported any new product developments or technological advancements in this reporting period, suggesting a potential area for future growth[99]. Financial Management and Investments - The company completed a significant asset sale, divesting its solar business subsidiaries, enhancing its focus on medical information and services, and optimizing its asset structure[44]. - The company reported an investment income of ¥21.06 million, a significant increase of 9,646.46% compared to the previous year[53]. - The company completed a major asset sale, transferring 100% equity of its solar subsidiaries, which allowed it to focus on medical information technology and services[56]. - The company plans to repurchase shares with a total amount between CNY 15 million and CNY 30 million, aimed at enhancing investor confidence[75]. - The company has implemented a long-term incentive mechanism, including employee stock ownership plans, to enhance employee motivation and cohesion[77]. Shareholder and Equity Management - The company has a total of 36,336 common shareholders as of the end of the reporting period[127]. - The largest shareholder, Mianyang Haoxiang Holdings Co., Ltd., holds 49,220,145 shares, accounting for 16.07% of the total shares[129]. - The company has not experienced any changes in its total number of shares or capital structure during the reporting period[126]. - The company reported a decrease in retained earnings by 28,327,457.34 RMB during the period, impacting overall equity[156]. - The company’s total equity at the end of the previous period was RMB 1,524.331066 billion, indicating a significant change in equity over the reporting periods[164]. Legal and Compliance - The company has no major litigation or arbitration matters during the reporting period, ensuring a stable legal environment for operations[98]. - There are no significant changes in the integrity status of the company and its controlling shareholders during the reporting period, indicating compliance with legal obligations[98]. - The company has not disclosed any major related party transactions that have not been previously announced, maintaining transparency in its operations[99]. - The company has not reported any major contracts or their performance issues during the reporting period, reflecting stable operational management[105]. Guarantees and Financial Obligations - The company provided a total of guarantees amounting to ¥48,000,000 for the subsidiary, with a guarantee period from August 29, 2024, to August 29, 2028, and no defaults reported[106]. - The company has established a pattern of providing guarantees with substantial amounts, indicating a strategic approach to financial management and risk mitigation[106][107]. - The total guarantee amount (excluding guarantees to subsidiaries) at the end of the reporting period is ¥264,674,173.08, which accounts for 31.97% of the company's net assets[109]. - The company has no overdue guarantees that may incur joint liability for repayment[109]. Accounting Policies and Financial Reporting - The financial statements are prepared based on the assumption of going concern, with no significant doubts regarding the company's ability to continue operations within the next 12 months[169]. - The accounting policies include revenue recognition, depreciation of investment properties, and capitalization of research and development expenses, tailored to the company's operational characteristics[170]. - The company adheres to the accounting standards set by the Ministry of Finance and ensures that the financial statements accurately reflect its financial position and performance[171]. - The company recognizes impairment losses on financial assets based on expected credit losses, which are the weighted average of credit losses adjusted for default risk[200].

证券代码：603990 证券简称：麦迪科技 公告编号：2025-053 苏州麦迪斯顿医疗科技股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 募集资金的管理情况 为规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者利 益，本公司根据《公司法》《证券法》《上市公司监管指引第2号——上市公司 募集资金管理和使用的监管要求》及《上海证券交易所上市公司自律监管指引 第1号—规范运作》等有关法律、法规和规范性文件的规定，结合公司实际情况， 公司制定了《管理及使用制度》。根据《管理及使用制度》，本公司对募集资 金采用专户存储制度，在银行设立募集资金专户进行专户管理。 公司于2020年11月26日，连同保荐机构东吴证券股份有限公司分别与中国 工商银行股份有限公司苏州阊胥路支行、浙商银行苏州分行营业部、中国民生 银行股份有限公司太仓支行、江苏江阴农村商业银行股份有限公司苏州分行营 业部签订了《募集资金三方监管协议》，明确了各方的权利和义务。三方监管 协议与 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-054 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日召开的第四届董事会第三十四次会议审议通过了《关于回购公司第三期员工持 股计划未解锁股份暨第三期员工持股计划终止的议案》，根据中国证监会《关于 上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》及《上市公司股份回购规则》的相关规定，公司将 回购第三期员工持股计划（以下简称"本次员工持股计划"）未能解锁的 1,037,300 股公司股票。现将具体情况公告如下： 一、第三期员工持股计划的基本情况 公司于 2024 年 6 月 7 日、2024 年 6 月 24 日召开的第四届董事会第二十次会 议、第四届监事会第十次会议、2024 年第三次临时股东大会审议通过了《关于< 苏州麦迪斯顿医疗科技股份有限公司第三期员工持股计划（草案）>及其摘要的 议案》《关于<苏州麦迪斯顿医疗科技股份有限公司第三期员工持股计划管理办法 （草案）>的议案》《关于提请股东大会授权董事会办理公司第三期员工持股计划 有关事项的议案》。 20 ...

Group 1 - The core point of the article highlights the financing activities of Madi Technology, indicating a net sell-off in recent trading days [1] - On August 15, Madi Technology had a financing buy amount of 0.12 billion, ranking 1251st in the two markets, with a financing repayment amount of 0.17 billion, resulting in a net sell of 4.95 million [1] - Over the last three trading days (August 13-15), Madi Technology received financing buys of 0.16 billion, 0.16 billion, and 0.12 billion respectively [1] Group 2 - In terms of securities lending, on August 15, Madi Technology had no shares sold or net sold in the securities lending market [1]

Investment Rating - The report rates the industry as "Overweight," indicating that it is expected to outperform the overall market [8]. Core Insights - The demand for health and wellness service robots is driven by aging population trends, technological advancements, and supportive policies [3]. - By 2024, the population aged 60 and above in China is projected to exceed 300 million, accounting for 22% of the total population, creating a significant service gap in rehabilitation and care [3]. - The Ministry of Industry and Information Technology has issued policies to promote the application of intelligent elderly care robots, facilitating industry implementation [3]. - Rapid advancements in both hardware and software technologies are making the deployment of health and wellness robots feasible [3]. Summary by Sections Demand Side - The aging population is creating a pressing need for health and wellness robots, which are seen as key solutions to labor shortages in care settings [3]. Policy Support - The government is actively promoting the integration of robots in elderly care through various policies, enhancing the industry's growth prospects [3]. Technological Development - Significant progress in relevant technologies, including sensors, batteries, and algorithms, is enabling the practical application of health and wellness robots across various scenarios [3]. Market Opportunities - The health and wellness robot market is vast, with rigid demand. Key companies to watch include: - Ousheng Electric, focusing on intelligent care services for bedridden patients [3]. - Zhongjian Technology, which is developing humanoid robots for elderly care [3]. - Madi Technology and Ubtech, collaborating on AI services in healthcare [3]. - Songlin Technology, planning to expand into health robots and AI companionship [3]. - Rongtai Health, launching smart health and therapy robots for home use [3]. - Sanhui Electric, investing in intelligent therapy robots [3]. - Beiqing Song, establishing a subsidiary for massage robots [3]. - Yijiahe, accelerating its presence in high-end health and smart home markets [3]. - Meihu Co., providing core components for elderly care robots [3].

Core Viewpoint - The company is focusing on developing integrated solutions in the fields of low-altitude rescue and health care robotics, leveraging its proprietary technology and addressing market challenges. Group 1: Company Developments - The company has launched a fully autonomous AED drone rescue solution, achieving a 4-minute emergency response time, which is an improvement over the traditional 15-minute response time with ambulances [2][4]. - The company is not manufacturing drones but providing comprehensive low-altitude rescue solutions, including software and control systems [2][4]. - The company is currently not involved in the brain-computer interface sector but is monitoring advancements in this area for potential applications in rehabilitation and human-computer interaction [2]. Group 2: Market Position and Challenges - The health care robotics industry is still in its early stages, facing challenges such as low public awareness, high costs, and a lack of standardized regulations [3]. - The company aims to build a smart health management platform that integrates intelligent interaction and health management, focusing on deep integration of software and hardware [3]. - The company is positioning itself as a leading player in low-altitude medical rescue, with plans to enhance urban emergency medical systems through its innovative solutions [3][4]. Group 3: Financial Insights - On August 8, the company’s stock closed at 15.05 yuan, down 1.51%, with a trading volume of 131,300 shares and a turnover of 198 million yuan [1]. - The net outflow of main funds on August 8 was 33.96 million yuan, accounting for 17.18% of the total turnover, while retail investors showed a net inflow of 31.15 million yuan, representing 15.76% of the total turnover [5][7].

Group 1 - The core viewpoint of the news is that Madi Technology (603990) has experienced a decline in stock price and significant changes in its financial performance as of the first quarter of 2025 [1][3] - As of August 8, 2025, Madi Technology's stock closed at 15.05 yuan, down 1.51%, with a turnover rate of 4.29% and a trading volume of 131,300 hands, amounting to 198 million yuan [1] - The net outflow of main funds today was 33.96 million yuan, accounting for 17.18% of the transaction amount, with large orders showing a net outflow of 20.07 million yuan [1] Group 2 - For the first quarter of 2025, Madi Technology reported total operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13%, while net profit attributable to shareholders was 23.60 million yuan, a year-on-year increase of 138.55% [1] - The company has a current ratio of 2.95, a quick ratio of 2.82, and a debt-to-asset ratio of 34.04% [1] - Madi Technology, established in 2009 and located in Suzhou, focuses on research and experimental development, with a registered capital of 3.06 billion yuan [1][2] Group 3 - Madi Technology has made investments in 9 companies and participated in 3,031 bidding projects, holding 84 trademark registrations and 168 patents [2]